Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, announces the availability of DecisionBase 9, an interactive decision tool that reveals the commercial opportunity of drugs in development and allows pharmaceutical and biotechnology organizations to compare those drugs with their own proprietary compounds. The unique database covers 35 diseases in a variety of therapeutic areas such as cardiovascular, central nervous system, oncology, immune and inflammatory disorders, infectious disease, psychiatric diseases, metabolic disorders, and other high- interest disease states.

  DecisionBase 9 allows users to perform the following forecasting tasks:   * Access information about and evaluate the potential for a specific drug     or disease.   * Drill down to a rich data set to understand current treatment and market     dynamics.   * Compare and contrast the unmet need and opportunity for proprietary     drug(s) against the future gold standard.  

New to DecisionBase 9 is the Drug Development Opportunity Profile, a feature that allows business development departments within pharmaceutical companies to better predict the impact of new drugs on the market. Using a combination of in-depth interviews with high-prescribing physicians and market analysis, the Drug Development Opportunity Profile uncovers the drug in development for a specific disease that will have a major impact on physician prescribing habits.

"The new Drug Development Opportunity Profile offers a unique insight into the potential of new drugs. It analyzes how the drugs will be received by the doctors on the frontlines," said Sarah Fuller, president of Decision Resources. "The profile marries the ideal with the practical. The ideal drug that a physician desires might not ever be feasible. The Drug Development Opportunity Profile can pinpoint which drug or drugs soon to be marketed comes the closest to addressing the physicians' needs. This type of analysis allows companies to better understand how much dollar and market share their drug will win."

About DecisionBase 9

DecisionBase 9 is built on insights from leading published studies, interviews with hundreds of thought-leading physicians and researchers from seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan), and input from Decision Resources' staff of therapeutic area experts. Its breadth of coverage, depth of analysis, and flexible modeling make DecisionBase an ideal tool for organizations looking to make strategic choices, model options, forecast potential, license new drugs, and achieve commercial success.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Decision Resources and PharMetrics Announce the Availability of First DecisionMETRICS Indication -- Dyslipidemia

View Now